Europe falling behind USA and China as attractive for life sciences sector

22 April 2013

Intellectual property specialists Marks & Clerk’s latest Life Sciences Report unveils the changing landscape within the sector, noting that the USA and China dominate rankings for market attractiveness, with Europe coming a poor third, only just ahead of India and South East Asia

Two thirds of respondents state that the situation regarding funding and investment has yet to recover from the post-financial crisis dip, and only one in five feel that the economic situation has improved for their organisation in the last 12 months. A majority (63%) also predicts major consolidation in the sector over the next three years

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >